Edition:
United Kingdom

Global Blood Therapeutics Inc (GBT.OQ)

GBT.OQ on NASDAQ Stock Exchange Global Select Market

37.81USD
19 Oct 2018
Change (% chg)

$-0.35 (-0.92%)
Prev Close
$38.16
Open
$38.36
Day's High
$39.86
Day's Low
$37.53
Volume
672,244
Avg. Vol
324,483
52-wk High
$68.05
52-wk Low
$30.00

Chart for

About

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The... (more)

Overall

Beta: --
Market Cap(Mil.): $1,412.94
Shares Outstanding(Mil.): 43.68
Dividend: --
Yield (%): --

Financials

  GBT.OQ Industry Sector
P/E (TTM): -- 85.41 33.64
EPS (TTM): -2.47 -- --
ROI: -37.53 0.21 14.27
ROE: -37.85 1.17 15.99

BRIEF-GBT Signs Licensing Agreement For Inclacumab To Treat Vaso-Occlusive Crisis

* GBT EXPANDS SICKLE CELL DISEASE PIPELINE WITH WORLDWIDE LICENSING AGREEMENT FOR INCLACUMAB FOR THE TREATMENT OF VASO-OCCLUSIVE CRISIS

23 Aug 2018

GBT's drug meets trial goal, investors skeptical of speedy approval

Global Blood Therapeutics Inc's sickle cell disease treatment met the main goal of a late-stage trial, but scepticism over whether the drug would get an accelerated review from health regulators pushed its shares down 12 percent.

27 Jun 2018

UPDATE 3-GBT's drug meets trial goal, investors skeptical of speedy approval

* Shares fall as much as 12 pct (Adds details from conference call, analyst comments; updates share move)

27 Jun 2018

Global Blood Therapeutics' sickle cell disease drug succeeds in trial

June 27 Global Blood Therapeutics Inc said on Wednesday its experimental drug met the main goal of a late-stage trial testing it in patients with sickle cell disease.

27 Jun 2018

BRIEF-GBT Q1 Loss Per Share $0.87

* GBT REPORTS RECENT BUSINESS PROGRESS AND FIRST QUARTER 2018 FINANCIAL RESULTS

07 May 2018

Competitors

  Price Chg
Bristol-Myers Squibb Co (BMY.N) $54.30 -1.68
Bristol-Myers Squibb Co (BMYMP.PK) $1,050.20 --
Novartis AG (NOVN.S) CHF87.04 +1.16
bluebird bio Inc (BLUE.OQ) $120.70 -1.44
Pfizer Inc. (PFE.N) $44.50 +0.50
Roche Holding Ltd. (ROG.S) CHF244.95 +6.40
Roche Holding Ltd. (RO.S) CHF245.20 +5.80

Earnings vs. Estimates